Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
Brain Amyloid Imaging - FDA Approval of Florbetapir F18 Injection
NEJM 367:885-887, Yang, L.,et al, 2012
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
NEJM 355:2652-2663, Small,G.W.,et al, 2006
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Potentially Reversible Conditions in 1000 Consecutive Memory Clinic Patients
JNNP 73:390-394, Hejl,A.,et al, 2002
Evaluation of CSf-tau and CSF-AB42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Arch Neurol 58:373-379,349, Andreasen,N.,et al, 2001
Altered Brain Activation in Cognitively Intact Individuals at High Risk for Alzheimer's Disease
Neurol 53:1391-1396, Smith,C.D.,et al, 1999
Drop the Alzheimer's Drop Test
Neurol 50:588-591, Kardon,R.H., 1998
Longitudinal Study of CSF Levels of Tau, A beta 1-40, and A beta 1-42 (43) in Alzheimer's Disease
Ann Neurol 44:17-26, 61998., Kanai,M.,et al, 1998
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Response of the Pupil to Tropicamide is not a Reliable Test of Alzheimer Disease
Arch Neurol 54:155-159, FitzSimon,J.S.,et al, 1997
Assessment of CSF Levels of Tau Protein in Mildly Demented Patients with Alzheimer's Disese
Neurol 48:632-635, Galasko,D.,et al, 1997
Pupil Dilation to Tropicamide is not Specific for Alzheimer Disease
Arch Neurol 54:841-844, Growdon,J.H.,et al, 1997
Apolipoprotein E Genotyping in Alzheimer's Disease
Lancet 347:1091-1095, Tanzi,R.,et al, 1996
Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the e4Allele for Apolipoprotein E
NEJM 334:752-758, 7911996., Reiman,E.M.,et al, 1996
Noninvasive Perfusion MRI in Alzheimer's Disease:A Preliminary Report
Neurol 47:1339-1342, Sandson,T.A.,et al, 1996
Genetic Factors in Alzheimer's Disease:A Review of Recent Advances
Ann Neurol 40:829-840, Levy-Lahad,E.&Bird,T.D., 1996
Prospective CT Confirms Differnces Between Vascular and Alzheimer's Dementia
Stroke 26:735-742, Meyer,J.S.,et al, 1995
Statement of Use of Apolipoprotein E Testing for Alzheimer Disease
JAMA 274:1627-1629, Farrer,L.A.,et al, 1995
Electroencephalography as an Aid in the Exclusion of Alzheimer's Disease
Arch Neurol 51:280-284, Robinson,D.J.,et al, 1994
Management of Neurological Disorders:Dementia
JNNP 57:1451-1456, Rossor,M.N., 1994
Amygdala Atrophy in Alzheimer's Disease, An In Vivo MRI Study
Arch Neurol 50:941-945, Cuenod,C.A.,et al, 1993
Blinded Clinical Evaluation of Positron Emission Tomography for Diagnosis of Probable Alzheimer's Disease
Neurol 42:765-770, Powers,W.J.,et al, 1992
Detection in Life of Confirmed Alzheimer's Disease, Medial Temporal Lobe Atrophy by Computed Tomography
Lancet 340:1179-1183, Jobst,K.A.,et al, 1992
Anomalous Molecular Form of Acetylcholinesterase in CSF in Histologically Diagnosed Alzheimer's Disease
Lancet 337:447-450, Navaratnam,D.S.,et al, 1991
Serial Visual Evoked Potential Recordings in Alzheimer's Disease
BMJ 293:9-10, Orwin,A.,et al, 1986
Positron Emission Tomography in Alzheimer's Disease
Neurol 36:879-887, Duara,R.,et al, 1986
Cerebrospinal Fluid Acetylcholinesterase Activity in Senile Dementia of the Alzheimer Type
Ann Neurol 17:46-48, Tune,L.,et al, 1985